BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mirzaei S, Zarrabi A, Hashemi F, Zabolian A, Saleki H, Azami N, Hamzehlou S, Farahani MV, Hushmandi K, Ashrafizadeh M, Khan H, Kumar AP. Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery. Antioxidants (Basel) 2021;10:349. [PMID: 33652780 DOI: 10.3390/antiox10030349] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 29.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang J, Xu H, Cho WCS, Cheuk W, Li Y, Huang Q, Yang W, Xian Y, Lin Z. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway. J Exp Clin Cancer Res 2022;41:90. [DOI: 10.1186/s13046-022-02270-z] [Reference Citation Analysis]
2 Du J, Sun J, Liu X, Wu Q, Shen W, Gao Y, Liu Y, Wu C. Preparation of C6 cell membrane-coated doxorubicin conjugated manganese dioxide nanoparticles and its targeted therapy application in glioma. European Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.ejps.2022.106338] [Reference Citation Analysis]
3 Jiang Q, Chen X, Tian X, Zhang J, Xue S, Jiang Y, Liu T, Wang X, Sun Q, Hong Y, Li C, Guo D, Wang Y, Wang Q. Tanshinone I inhibits doxorubicin-induced cardiotoxicity by regulating Nrf2 signaling pathway. Phytomedicine 2022;106:154439. [PMID: 36108374 DOI: 10.1016/j.phymed.2022.154439] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Behroozaghdam M, Dehghani M, Zabolian A, Kamali D, Javanshir S, Hasani Sadi F, Hashemi M, Tabari T, Rashidi M, Mirzaei S, Zarepour A, Zarrabi A, De Greef D, Bishayee A. Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action. Cell Mol Life Sci 2022;79:539. [PMID: 36194371 DOI: 10.1007/s00018-022-04551-4] [Reference Citation Analysis]
5 Mohamed BM, Ismail RS, Saleh IG, Abo-salem OM, El-sayed EM. Olmesartan ameliorates cyclophosphamide-induced hemorrhagic cystitis in rats via Nrf2/HO-1 signaling pathway. Tissue and Cell 2022;78:101877. [DOI: 10.1016/j.tice.2022.101877] [Reference Citation Analysis]
6 Wang X, Yan J, Ye Z, Zhang Z, Wang S, Hao S, Shen B, Wei G. Reorganization of 3D chromatin architecture in doxorubicin-resistant breast cancer cells. Front Cell Dev Biol 2022;10:974750. [PMID: 36003143 DOI: 10.3389/fcell.2022.974750] [Reference Citation Analysis]
7 Hu Q, Yammani RD, Brown-harding H, Soto-pantoja DR, Poole LB, Lukesh JC. Mitigation of doxorubicin-induced cardiotoxicity with an H2O2-Activated, H2S-Donating hybrid prodrug. Redox Biology 2022;53:102338. [DOI: 10.1016/j.redox.2022.102338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mirzaei S, Paskeh MDA, Okina E, Gholami MH, Hushmandi K, Hashemi M, Kalu A, Zarrabi A, Nabavi N, Rabiee N, Sharifi E, Karimi-Maleh H, Ashrafizadeh M, Kumar AP, Wang Y. Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. J Exp Clin Cancer Res 2022;41:214. [PMID: 35773731 DOI: 10.1186/s13046-022-02406-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
9 Jiang T, He Y. Recent Advances in the Role of Nuclear Factor Erythroid-2-Related Factor 2 in Spinal Cord Injury: Regulatory Mechanisms and Therapeutic Options. Front Aging Neurosci 2022;14:851257. [PMID: 35754957 DOI: 10.3389/fnagi.2022.851257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Ashrafizadeh M, Zarrabi A, Karimi‐maleh H, Taheriazam A, Mirzaei S, Hashemi M, Hushmandi K, Makvandi P, Nazarzadeh Zare E, Sharifi E, Goel A, Wang L, Ren J, Nuri Ertas Y, Kumar AP, Wang Y, Rabiee N, Sethi G, Ma Z. (Nano)platforms in bladder cancer therapy: Challenges and opportunities. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Fernandes AS. Redox-Active Molecules as Therapeutic Agents. Antioxidants 2022;11:1004. [DOI: 10.3390/antiox11051004] [Reference Citation Analysis]
12 Ashrafizadeh M, Rabiee N, Prem Kumar A, Sethi G, Zarrabi A, Wang Y. Long noncoding RNAs (lncRNAs) in pancreatic cancer progression. Drug Discov Today 2022:S1359-6446(22)00202-1. [PMID: 35589014 DOI: 10.1016/j.drudis.2022.05.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Mirzaei S, Saghari S, Bassiri F, Raesi R, Zarrabi A, Hushmandi K, Sethi G, Tergaonkar V. NF-κB as a regulator of cancer metastasis and therapy response: A focus on epithelial-mesenchymal transition. J Cell Physiol 2022. [PMID: 35561232 DOI: 10.1002/jcp.30759] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
14 Entezari M, Sadrkhanloo M, Rashidi M, Asnaf SE, Taheriazam A, Hashemi M, Ashrafizadeh M, Zarrabi A, Rabiee N, Hushmandi K, Mirzaei S, Sethi G. Non-coding RNAs and macrophage interaction in tumor progression. Crit Rev Oncol Hematol 2022;:103680. [PMID: 35405273 DOI: 10.1016/j.critrevonc.2022.103680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
15 Yang W, Wang Y, Zhang P, Wang T, Li C, Tong X, Zeng X, Yin Y, Tao K, Li R, Kolaczkowska E. Hepatoprotective Role of 4-Octyl Itaconate in Concanavalin A-Induced Autoimmune Hepatitis. Mediators of Inflammation 2022;2022:1-17. [DOI: 10.1155/2022/5766434] [Reference Citation Analysis]
16 Ashrafizadeh M, Saebfar H, Gholami MH, Hushmandi K, Zabolian A, Bikarannejad P, Hashemi M, Daneshi S, Mirzaei S, Sharifi E, Kumar AP, Khan H, Heydari Sheikh Hossein H, Vosough M, Rabiee N, Thakur Kumar V, Makvandi P, Mishra YK, Tay FR, Wang Y, Zarrabi A, Orive G, Mostafavi E. Doxorubicin-loaded graphene oxide nanocomposites in cancer medicine: Stimuli-responsive carriers, co-delivery and suppressing resistance. Expert Opin Drug Deliv 2022. [PMID: 35152815 DOI: 10.1080/17425247.2022.2041598] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
17 Rahman MA, Ahmed KR, Rahman MH, Park MN, Kim B. Potential Therapeutic Action of Autophagy in Gastric Cancer Managements: Novel Treatment Strategies and Pharmacological Interventions. Front Pharmacol 2022;12:813703. [DOI: 10.3389/fphar.2021.813703] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Liao ZQ, Jiang YN, Su ZL, Bi HL, Li JT, Li CL, Yang XL, Zhang Y, Xie X. Rutaecarpine Inhibits Doxorubicin-Induced Oxidative Stress and Apoptosis by Activating AKT Signaling Pathway. Front Cardiovasc Med 2021;8:809689. [PMID: 35071368 DOI: 10.3389/fcvm.2021.809689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Entezari M, Hashemi D, Taheriazam A, Zabolian A, Mohammadi S, Fakhri F, Hashemi M, Hushmandi K, Ashrafizadeh M, Zarrabi A, Ertas YN, Mirzaei S, Samarghandian S. AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation. Biomed Pharmacother 2022;146:112563. [PMID: 35062059 DOI: 10.1016/j.biopha.2021.112563] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
20 Mad-Adam N, Rattanaburee T, Tanawattanasuntorn T, Graidist P. Effects of trans-(±)-kusunokinin on chemosensitive and chemoresistant ovarian cancer cells. Oncol Lett 2022;23:59. [PMID: 34992691 DOI: 10.3892/ol.2021.13177] [Reference Citation Analysis]
21 El Bakary NM, Abdel-rafei MK, Maarouf RE, Mansour SZ, Thabet NM. Trans-resveratrol alleviates hepatic and renal injury in γ-irradiated rats. Hum Exp Toxicol 2022;41:096032712211428. [DOI: 10.1177/09603271221142817] [Reference Citation Analysis]
22 Yadav S, Ramesh K, Kumar P, Jo SH, Yoo SI, Gal YS, Park SH, Lim KT. Near-Infrared Light-Responsive Shell-Crosslinked Micelles of Poly(d,l-lactide)-b-poly((furfuryl methacrylate)-co-(N-acryloylmorpholine)) Prepared by Diels-Alder Reaction for the Triggered Release of Doxorubicin. Materials (Basel) 2021;14:7913. [PMID: 34947507 DOI: 10.3390/ma14247913] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
23 Cui T, Jiang W, Yang F, Luo J, Hu R, Cao H, Hu G, Zhang C. Molybdenum and cadmium co-induce hypothalamus toxicity in ducks via disturbing Nrf2-mediated defense response and triggering mitophagy. Ecotoxicol Environ Saf 2021;228:113022. [PMID: 34844167 DOI: 10.1016/j.ecoenv.2021.113022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
24 Reis-Mendes A, Padrão AI, Duarte JA, Gonçalves-Monteiro S, Duarte-Araújo M, Remião F, Carvalho F, Sousa E, Bastos ML, Costa VM. Role of Inflammation and Redox Status on Doxorubicin-Induced Cardiotoxicity in Infant and Adult CD-1 Male Mice. Biomolecules 2021;11:1725. [PMID: 34827723 DOI: 10.3390/biom11111725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Abd El-Hameed NM, Abd El-Aleem SA, Khattab MA, Ali AH, Mohammed HH. Curcumin activation of nuclear factor E2-related factor 2 gene (Nrf2): Prophylactic and therapeutic effect in nonalcoholic steatohepatitis (NASH). Life Sci 2021;285:119983. [PMID: 34599938 DOI: 10.1016/j.lfs.2021.119983] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
26 Mureşan M, Olteanu D, Filip GA, Clichici S, Baldea I, Jurca T, Pallag A, Marian E, Frum A, Gligor FG, Svera P, Stancu B, Vicaș L. Comparative Study of the Pharmacological Properties and Biological Effects of Polygonum aviculare L. herba Extract-Entrapped Liposomes versus Quercetin-Entrapped Liposomes on Doxorubicin-Induced Toxicity on HUVECs. Pharmaceutics 2021;13:1418. [PMID: 34575493 DOI: 10.3390/pharmaceutics13091418] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
27 Wang X, Yan J, Shen B, Wei G. Integrated Chromatin Accessibility and Transcriptome Landscapes of Doxorubicin-Resistant Breast Cancer Cells. Front Cell Dev Biol 2021;9:708066. [PMID: 34395436 DOI: 10.3389/fcell.2021.708066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Hussain H, Ali I, Wang D, Hakkim FL, Westermann B, Ahmed I, Ashour AM, Khan A, Hussain A, Green IR, Shah STA. Glycyrrhetinic acid: a promising scaffold for the discovery of anticancer agents. Expert Opin Drug Discov 2021;:1-20. [PMID: 34294017 DOI: 10.1080/17460441.2021.1956901] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
29 Emanuele S, Celesia A, D'Anneo A, Lauricella M, Carlisi D, De Blasio A, Giuliano M. The Good and Bad of Nrf2: An Update in Cancer and New Perspectives in COVID-19. Int J Mol Sci 2021;22:7963. [PMID: 34360732 DOI: 10.3390/ijms22157963] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
30 Alsherbiny MA, Bhuyan DJ, Radwan I, Chang D, Li CG. Metabolomic Identification of Anticancer Metabolites of Australian Propolis and Proteomic Elucidation of Its Synergistic Mechanisms with Doxorubicin in the MCF7 Cells. Int J Mol Sci 2021;22:7840. [PMID: 34360606 DOI: 10.3390/ijms22157840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
31 Mirzaei S, Abadi AJ, Gholami MH, Hashemi F, Zabolian A, Hushmandi K, Zarrabi A, Entezari M, Aref AR, Khan H, Ashrafizadeh M, Samarghandian S. The involvement of epithelial-to-mesenchymal transition in doxorubicin resistance: Possible molecular targets. Eur J Pharmacol 2021;908:174344. [PMID: 34270987 DOI: 10.1016/j.ejphar.2021.174344] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
32 Mirzaei S, Gholami MH, Zabolian A, Saleki H, Farahani MV, Hamzehlou S, Far FB, Sharifzadeh SO, Samarghandian S, Khan H, Aref AR, Ashrafizadeh M, Zarrabi A, Sethi G. Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer. Pharmacol Res 2021;171:105759. [PMID: 34245864 DOI: 10.1016/j.phrs.2021.105759] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 26.0] [Reference Citation Analysis]
33 Solís KH, Romero-Ávila MT, Guzmán-Silva A, García-Sáinz JA. The LPA3 Receptor: Regulation and Activation of Signaling Pathways. Int J Mol Sci 2021;22:6704. [PMID: 34201414 DOI: 10.3390/ijms22136704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Farkhondeh T, Pourbagher-Shahri AM, Azimi-Nezhad M, Forouzanfar F, Brockmueller A, Ashrafizadeh M, Talebi M, Shakibaei M, Samarghandian S. Roles of Nrf2 in Gastric Cancer: Targeting for Therapeutic Strategies. Molecules 2021;26:3157. [PMID: 34070502 DOI: 10.3390/molecules26113157] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
35 Barrera G, Cucci MA, Grattarola M, Dianzani C, Muzio G, Pizzimenti S. Control of Oxidative Stress in Cancer Chemoresistance: Spotlight on Nrf2 Role. Antioxidants (Basel) 2021;10:510. [PMID: 33805928 DOI: 10.3390/antiox10040510] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]